

**Daoud K. Abu-Hamdan, M.D.**

**Office Address**

VA Medical Center:  
4646 John R  
Detroit, MI 48202  
Telephone: (313) 576-1000

**EDUCATION:**

Baccalaureate: Al-Hussein College, Amman, Jordan, 1962  
Graduate: M.D., Faculty of Medicine, Universidad Complutense, Madrid, Spain,  
1968

**TRAINING:**

1969 - 1973 Medical Officer, Jordanian Royal Medical Service, Jordan  
1971 - 1972 Rotating Internship, Base Military Hospital, Amman, Jordan  
1973 - 1974 Rotating Medical Intern, Mount Vernon Hospital, Mount Vernon, New  
York  
1974 - 1975 Medical Resident, Mount Vernon Hospital, Mount Vernon, New York  
1975 - 1977 Medical Resident, New Rochelle Hospital Medical Center, New  
Rochelle, New York  
1977 - 1979 Nephrology Fellowship, Wayne State University Affiliated Hospitals  
Program, Detroit, Michigan

**FACULTY APPOINTMENTS:**

- 1979 - 1990      Assistant Professor of Medicine, Wayne State University School of Medicine, Detroit, Michigan
- 1990 - Present      Associate Professor of Medicine, Wayne State University School of Medicine, Detroit, Michigan**

**HOSPITAL APPOINTMENTS:**

- 1979 - 1990      Staff, Nephrology Section, Medical Service, VA Medical Center, Allen Park, Michigan
- 1980 - Present      Staff, Department of Medicine, Hutzel Hospital, Detroit, Michigan**
- 1982 - Present      Staff, Department of Medicine, Detroit Receiving Hospital and University Health Center, Detroit, Michigan**
- 1983 - Present      Staff, Department of Medicine, Harper-Grace Hospitals, Detroit, Michigan**
- 2005 – Present      Staff, Karmanos cancer hospital, Detroit, Michigan**
- 1990 - Present      Chief, Nephrology Section, Medical Service, VA Medical Center, Detroit, Michigan**
- 1990 - Present      Chair, End Stage Renal Disease Committee**
- 2005 –Present      Chair, Peer Review Committee, VA Medical Center, Detroit, Michigan**

**MAJOR PROFESSIONAL SOCIETIES:**

American Federation for Clinical Research  
American Society of Nephrology  
International Society of Nephrology  
American College of Physicians  
National Kidney Foundation  
American Society of Hypertension  
Arab American Medical Association

**LICENSURE AND BOARD CERTIFICATION:**

Licensure - State of Michigan  
1977 - American Board of Internal Medicine  
1980 - American Board of Nephrology

**SERVICE:**

**Patient Care:**

**Tuesday PM: Renal Clinic/Primary care - VA Medical Center, Detroit, Michigan**  
**Wednesday PM: Renal Clinic/Primary Care - VA Medical Center, Detroit, Michigan**  
**Thursday AM: Renal Clinic/Primary Care - VA Medical Center, Detroit, Michigan**

**Professional Consultation:**

**Renal Consultations: Eight months/year at VA Medical Center**  
**9 Weekend coverage of the whole medical center**

**Hemodialysis Rounding: Eight months/year at VA Medical Center**

**Internal Medicine Ward Rounds: ONE month/year at VA Medical Center**

**TEACHING:**

**July 1979 - Present Courses taught at Wayne State University in last five years.**  
**Participated in teaching Nephrology seminars for**  
**sophomore students ten hours/yearly.**  
**Renal Pathophysiology Lecture Year II students (1 hour)**  
**Professor's round with nephrology fellows (one hour every**  
**4 months).**  
**Basic Science Lecture for nephrology section (one**  
**hour/year)**

**GRANT SUPPORT:**

1988 - 1990 Ross Laboratories (Co-Investigator). Effect of a dietary protein modification on the progress of chronic renal failure, \$396,110.

1988 - 1991 VA Merit Review (Co-Investigator). Gonadal Dysfunction in Men with Uremia, \$59,000.

1988 - 1991 NIH (Co-Investigator). Gonadal Dysfunction in Chronic Renal Failure, \$196,000.

1989 - 1990 Wyeth-Ayerst Laboratories (Co-Investigator). A pharmacodynamic and pharmacokinetics study of intravenously administered reconstituted depolymerized heparin in normal subjects and in patients with chronic renal insufficiency, \$158,101.

- 1994 Merck Cozaar Study #C0Z345 (Co-Investigator). A prospective, double-blind, randomized comparison of two treatment regimens: Cozaar and Hyzaar versus Procardia XL in the treatment of elderly patients with mild-to-moderate hypertension, \$13,000.
- 1994 - 1995 Bristol-Myers Squibb (Principle Investigator). Factorial trial of the efficacy and safety of multiple dosages of SR47436 (Bristol-Myers Squibb - 186295) and HCTZ in mild-to-moderate hypertension.
- 1998 - 1999 Bristol-Myers Squibb (Co-Investigator). Multi-center, randomized, double-blind, lisinopril placebo controlled trial of the antihypertensive efficacy and safety of omapatrilat in black subjects with mild to moderate hypertension.
- 1998 – 2000 VA Cooperative Study #440 (Principle Investigator). Anti-Thrombotic Agents In The Prevention Of Hemodialysis Access Thrombosis, Cost \$85,620.00
- 1995 - 2001 Merck LIFE Study #133-00/COZ368 (Principle Investigator). Losartan intervention for endpoint reduction in hypertension.
- 2000 - 2001 A Study evaluating the Initiation of Fixed Doses of Novel Erythropoiesis Stimulating Protein (NESP) Therapy in Subjects with Chronic Renal Insufficiency (CRI) \$15,000.00 yearly.(PI)
- 2001 - 2007 VA Cooperative Study #453 (Principal Investigator). Homocysteinemia in Kidney and End Stage Renal Disease Study (HOST). \$70,000.00**
- 2002 - 2003 VA CSP#453 HOST-DNA. Genetic Tissue Banking for the HOST study (PI) \$3000.00
- 2002 - 2003 VA Cooperative Studies Programs # 476. Enhancing Quality of Informed consent-Development Phase (EQUIC-DP). (PI) \$3000.00
- 2004 -2005 (Amgen) Darbepoeitin alfa study 20030237. (PI) \$3300.00**

### **GRANT PROPOSALS (Submitted in the past)**

- 1982 NIH, (Co-Investigator). "Intestinal and Renal Zinc Transport: Role of Diet, Parahormone and Vitamin D", (approved, not funded).
- 1983 NIH, (Co-Investigator). "Intestinal and Renal Zinc Transport", (approved, not funded).

## **PUBLICATIONS:**

### **Original Observations in Refereed Journals**

1. Migdal, S.D., Slick, G.L., **Abu-Hamdan, D.K.**, and McDonald, F.D.: Phenytoin, renal function and renin release. *J Pharma Exp Thera* 215:304-306, 1980.
2. Mahajan, S.K., Carey, E., Kinhal, V., **Abu-Hamdan, D.K.**, Briggs, W.A., and McDonald, F.D.: Effect of correction of dialysis related hypoxemia on cardiac dysfunction during hemodialysis. *Clin Dial Transplant Forum* 10:110-113, 1980.
3. **Abu-Hamdan, D.K.**, Migdal, S.D., Whitehouse, R., Prasad, A.S., and McDonald, F.D.: Renal handling of zinc: Effect of cysteine infusion. *Amer J Phys* 241:F487-494, 1981.
4. Mahajan, S.K., Abraham, J., Bornstein, K., Hessberg, T., Migdal, S.D., **Abu-Hamdan, D.K.**, Prasad, A.S., Briggs, W.A. and McDonald, F.D.: Zinc metabolism and taste acuity in renal transplant recipients. *Kidney Int* 24(16):S310-314, 1983.
5. **Abu-Hamdan, D.K.**, Desai, S., Mahajan, S., Mueller, B., Briggs, W., Lynne-Davies, L., and McDonald, F.: Hypoxemia during hemodialysis using acetate versus bicarbonate dialysis. *Am J Nephrology* 4:248-253, 1984.
6. Mahajan, S.K., Abraham, J., Migdal, S.D., **Abu-Hamdan, D.K.**, and McDonald, F.D.: Effect of renal transplantation on zinc metabolism and taste acuity in uremia: A prospective study. *Transplantation* 38:6, 599-602, 1984.
7. Mahajan, S.K., Speck, J.A., Varghese, G.A., **Abu-Hamdan, D.K.**, Migdal, S.D., Prasad, A.S., and McDonald, F.D.: Zinc metabolism in nephrotic syndrome. *Nutrition Research, Supplement 1*, pp. 360-362, 1985.
8. **Abu-Hamdan, D.K.**, Mahajan, S.K., Migdal, S.D., Prasad, A.S., and McDonald, F.D.: Zinc tolerance test in uremia: Effect of ferrous sulfate and aluminum hydroxide. *Ann Int Med* 104:50-52, 1986.
9. Sondheimer, J.H., Mahajan, S.K., Rye, D.L., **Abu-Hamdan, D.K.**, Migdal, S.D., Prasad, A.S., and McDonald, F.D.: Elevated plasma copper levels in uremia. *Am J Clin Nutr* 47:896-899, 1988.
10. **Abu-Hamdan, D.K.**, Mahajan, S.K., Migdal, S.D., Prasad, A.S., and McDonald, F.D.: Zinc tolerance test in uremia: Effect of calcitriol supplementation. *J Am Coll Nutr* 7:235-240, 1988.
11. **Abu-Hamdan, D.K.**, Desai, H., Sondheimer, J., Felicetta, J., Mahajan, S., and McDonald, F.: Taste acuity and zinc metabolism in Captopril-treated hypertensive male patients. *Am J Hypertension* 1:303s-308s, 1988.

12. Mahajan, S.K., Bowersox, E., Rye, D.L., **Abu-Hamdan, D.K.**, McDonald, F.D., Prasad, A.S., Biersack, K.: Factors underlying abnormal zinc metabolism in uremia. *Kidney Int* 36:318-323, 1989.
13. Kozol, R., Wilson, R.F., Mahajan, S., **Abu-Hamdan, D.K.**, and Thomas, D.: Gastric Intramural Acidosis in patients with chronic renal failure. *Surgery* 113; 520-526, 1993.

#### **Published Review Articles**

1. **D.K. Abu-Hamdan.**, J.R. Sowers. Diabetes, Dyslipidemia, and Renal Disease in the Elderly. Council on geriatric cardiology. February 1998, pp 60-64.

#### **Original Observations Published in Book Form**

1. Ganji, S., Mahajan, S., **Abu-Hamdan, D.K.**, and Migdal, S.: Somatosensory evoked potential in uremia. *Progress in Artificial Organs, 1983*. K. Atsumi, M. Mackawa, and K. Ota (editors), ISAO Press, Cleveland, 1984, Vol 1, pp.436-438.
2. Mahajan, S.K., Migdal, S.D., Port, F.D., Rye, D.L., Abraham, J., **Abu-Hamdan, D.K.**, and McDonald, F.D.: Hypozincemia in patients undergoing CAPD. *Advances in Continuous Ambulatory Peritoneal Dialysis*, R. Khanna, et al (editors). University of Toronto Press, 1986, pp.65-69.
3. Mahajan, S.K., Rye, D.L., Rifat, S., Weissler, J., **Abu-Hamdan, D.K.**, and McDonald, F.D.: Hypercupremia in uremia: The role of artificial kidneys. *Blood Purification in Perspective: New Insight and Future Trends*. N.K. Man, et al (editors). ISAO Press, Cleveland, 1987, pp.63-66.

#### **Case Reports in Refereed Journals:**

1. 18. **Abu-Hamdan, D.K.**, Sondheimer, J.H. and Mahajan, S.K.: Cautopyreiophagia: A cause of life threatening hyperkalemia in a hemodialysis patient. *Am J Med* 79:517-519, 1985.

#### **Review in Patient Education Publication:**

1. **Abu-Hamdan, D.K.**, McDonald, F.D.: Zinc and Sexuality in renal failure. *NKF Family Focus* Vol 2 No. 4, Page 15, 1991.

### **Other:**

1. Björn Dahlöf, Devereux RB Hans Wedel for the life study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomized trial against atenolol. The Lancet: 359 pp: 995-1003, 2002. (D Abu-Hamdan named in appendix among primary investigators).
2. Kaufman JS, O'Connor TZ, Zhang JH et al for the Veteran Affairs Cooperative Study Group on Hemodialysis Access graft thrombosis. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003 Sep; 14(9):2313-21. (D Abu Hamdan named in appendix among primary investigators)
3. **Rex L. Jamison, Pamela Hartigan, J Michael Gaziano et al. Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. Clinical trials 2004; 1: 451-460. (Daoud K Abu-Hamdan named in appendix among primary investigators)**

### **PUBLISHED ABSTRACTS**

1. **Abu-Hamdan, D.K.**, Desai, H., Sondheimer, J., Felicetta, J., Mahajan, S., and McDonald, F.: Effects of Captopril on zinc status and taste acuity in hypertensive male patients. Kidney Int 31:294A, 1987.
2. Wood, M., Mahajan, S., Sillix, D., **Abu-Hamdan, D.K.**, Migdal, S., and McDonald, F.: Zinc metabolism and taste acuity in Cyclosporine-Prednisone treated renal transplant recipients. Kidney Int 31:361A, 1987.
3. Mahajan, S., Sillix, D., Wood, M., Bhat, S., Martin, J., **Abu-Hamdan, D.K.**, Migdal, S., and McDonald, F.: Lack of Post-transplant hypophosphatemia in Cyclosporine-Prednisone treated renal transplant recipients. Kidney Int 31:463A, 1987.
4. **Abu-Hamdan, D.K.**, Desai, H., Sondheimer, J., Felicetta, J., Mahajan, S., and McDonald, F.: Taste Acuity and Zinc (Zn) Metabolism in Captopril-treated hypertensive male patients. Clin Res 35:437A, 1987.
5. Mahajan, S., Bowersox, E., Rye, D., **Abu-Hamdan, D.K.**, Biersack, K., McDonald, F., and Prasad, A.: Zinc balance studies in uremia. Clin Res 36:868A, 1988.
6. Migdal, S.D., Mutchnick, M.G., Mahajan, S.K., **Abu-Hamdan, D.K.**, and McDonald, F.D.: Serum Thymosin B (TB) levels in patients chronic renal failure. Kidney Int 35:399, 1989.
7. Mahajan, S., Wang, H., **Abu-Hamdan, D.K.**, McDonald F. and Prasad, A.: Plasma and Cellular zinc in uremia. Kidney Int 35:399, 1989.

8. Khoury, S., Mahajan, S., **Abu-Hamdan, D.K.**, and Joshi, N.: The pattern of LH secretion and responsiveness to pulsatile GnRH in men with uremia. Clin Res 37:896, 1989.
9. Mahajan, S., Prasad, A., **Abu-Hamdan, D.K.**, Bowersox, L., McDonald, F., and Biersack, K.: Effect of vitamin D on zinc metabolism in uremia. Clin Res 37:932, 1989.
10. Mahajan, S., Prasad, A., **Abu-Hamdan, D.K.**, and Joshi, N.: Gonadal dysfunction in uremia: Luteinizing Hormone secretion and its responsiveness to gonadotrophin releasing hormone. Kidney Int 37:276, 1990.
11. Mahajan, S., **Abu-Hamdan, D.K.**, Prasad, A., Bowersox, L., McDonald, F., and Biersack, K.: Zinc metabolism in uremia: Effect of vitamin D on zinc balance and cellular zinc. Kidney Int 37:473, 1990.
12. Mahajan, S., Johnson, P., **Abu-Hamdan, D.K.**, Biersack, K., McDonald, F., and Prasad, A.: Zinc deficiency in uremia: Effect of vitamin D on cellular zinc, zinc balance and zinc absorption. Clin Res 38:258, 1990.
13. Diebel, L., Kozol, R., Mahajan, S., **Abu-Hamdan, D.K.**, and Thomas, D.: Gastric ischemia in patients with chronic renal failure. Proc Association of VA Surgeons, 1990.
14. Khoury, S., **Abu-Hamdan, D.K.**, Mahajan, S., Joshi, N. and Veldhuis, J.: Regulation of the reproductive axis in uremic men. Clin Res 39:265, 1991.
15. Kosgi S, Nimmagadda S, Jena-Mohanty M, Edelstein M, *Migdal SD*, **Abu-Hamdan D.** Macrocytosis in Dialysis Patients Internal Medicine, John D. Dingell VA Medical Center, Detroit, MI; Nephrology, Wayne State University American Society of Nephrology J Am Soc Nephrol 16: 872A, 2005
16. Jamison,R, Et Al, **Abu-Hamdan, D** listed as one of the participating PIs. Patients with advanced chronic kidney disease (ACKD) have unexpectedly high rates of death and progression to end stage renal disease (ESRD). J Am Soc Nephrol 17; 202A 2006.

## **PRESENTATIONS:**

### **National/International**

1. Effect of correction of dialysis related hypoxemia on cardiac dysfunction during hemodialysis (H), Annual Meeting of the Clinical Dialysis and Transplantation Forum, Washington, DC, November 1980.
2. Hypoxemia during bicarbonate dialysis, American Society of Nephrology 13th Annual Meeting, Washington, DC, November 1980.
3. Mechanism of hypoxemia during hemodialysis, American Thoracic Society, Detroit, Michigan, May 1981.

4. Zinc metabolism and taste acuity in renal transplant recipients, Third International Congress of Nutrition and Metabolism in Renal Disease, Marseille, France, September 1982.
5. Zinc metabolism in renal transplant patients, 23rd Annual Meeting of American College of Nutrition, Arlington, Virginia, October 1982.
6. Zinc deficiency in patients with nephrotic syndrome, 15th Annual Meeting of American Society of Nephrology, Chicago, Illinois, December 1982.
7. Zinc metabolism and taste acuity following renal transplantation, The American Federation for Clinical Research National Meeting, Washington, DC, April 1983.
8. Zinc metabolism in nephrotic syndrome, International Symposium on Health Effects and Interactions of Essential and Toxic Elements, Lund, Sweden, June 1983.
9. Somata-sensory evoked potentials in uremia, 4th Congress of the International Society for Artificial Organs, Kyoto, Japan, November, 1983.
10. Zinc absorption in uremia, National Meeting of the American Federation for Clinical Research, Washington, DC, May 1984.
11. Zinc absorption in uremia: Effect of phosphate binders, IXth International Congress of Nephrology, Los Angeles, California, June 1984.
12. Zinc absorption in uremia: Effect of phosphate binders and iron supplements, 25th Annual Meeting of the American College of Nutrition, Boston, Massachusetts, September 1984.
13. Copper metabolism in patients with renal disease, The National Meeting of the American Federation for Clinical Research, Washington, DC, May 3-6, 1985.
14. Effect of 1,25 (OH) D on zinc absorption in uremia, 26th Annual American College of Nutrition Meeting, Blacksburg, Virginia, July 22-24, 1985.
15. Copper metabolism in uremia: Effect of dialysis and zinc supplementation, 31st Annual Meeting of the American Society for Artificial Internal Organs, Atlanta, Georgia, May 1-3, 1985.
16. Hypercupremia in uremia: Role of artificial kidneys, Contemporary Management of End Stage Renal Disease, Marrakesh, Morocco, November 10-15, 1985.
17. Hypozincemia in patients undergoing CAPD, 6th National Conference on CAPD, Kansas City, Missouri, February 5-7, 1986.
18. Elevated plasma copper levels in uremia: The role of artificial kidneys, The American Federation for Clinical Research National Meeting, Washington, DC, May 2-5, 1986.
19. Taste Acuity and zinc metabolism in Captopril-treated hypertensive male patients, National Meeting of the American Federation for Clinical Research, San Diego, California, May 1-4, 1987.

20. Taste acuity and zinc metabolism in Captopril-treated hypertensive male patients, American Hypertension Society Meeting, New York, New York, May 17-21, 1987.
21. Factors underlying abnormal zinc metabolism in uremia, 5th International Congress on Nutrition and Metabolism in Renal Disease, Strasboug, France September 1-3, 1988.
22. Gonadal dysfunction in uremia: Luteinizing Hormone Secretion and its responsiveness to gonadotrophin releasing hormone. American Society of Nephrology Meeting, Washington, DC, December 3-6, 1989.
23. Zinc Deficiency in uremia: Effect of vitamin D on cellular zinc, zinc balance and zinc absorption. National meeting of the American Federation for Clinical Nephrology, Washington, DC, May 4-7, 1990.
24. Regulation of the reproductive axis in uremic men. National Meeting of the American Federation for Clinical Research, Seattle Washington, May 2-5, 1991.

### **Local/Regional**

1. Disparate urinary zinc (Zn) handling in response to Zn infusion and amino acids, Michigan Chapter ACP Annual Meeting, Boyne Highlands, Harbor Springs, Michigan, October 1979.
2. Disparate urinary zinc (Zn) handling in response to Zn infusion and amino acids, Department of Medicine Research Forum, Wayne State University, Detroit, Michigan, June 1979.
3. Hypoxemia during hemodialysis, Michigan Chapter American College of Physicians Annual Meeting, Boyne Highlands, Harbor Springs, Michigan, October, 1982.
4. Improvement of renal function after over three years on hemodialysis, Michigan Chapter ACP Annual Meeting, Traverse City, Michigan, October, 1982.
5. Zinc metabolism and taste acuity in renal transplant recipients, Michigan Chapter ACP Annual Meeting, Traverse City, Michigan, October 1982.
6. The role of acetate and blood/membrane interactions in dialysis-related hypoxemia, Regional Meeting of the American College of Physicians, Boyne Highlands, Harbor Springs, Michigan, October 1983.
7. Zinc Metabolism in Nephrotic Syndrome, Regional Meeting of the American College of Physicians, Boyne Highlands, Harbor Springs, Michigan, October 1983.
8. Effect of zinc supplementation and renal transplantation on uremic hyperprolactinemia, Regional Meeting of American College of Physicians, Michigan Chapter, Boyne Highlands, Harbor Springs, Michigan, October 11-14, 1984.
9. Increased renal zinc clearance on Captopril: Report of a case, Regional Meeting of American College of Physicians, Michigan Chapter, Boyne Highlands, Harbor Springs, Michigan, October 11-14, 1984.

10. Effect of phosphate binders and iron supplements on zinc absorption in uremia, Regional Meeting of American College of Physicians, Michigan Chapter, Boyne Highlands, Harbor Springs, Michigan, October 11-14, 1984.
11. Copper metabolism in patients with renal disease: Effect of dialysis, renal transplantation and zinc supplementation, Regional Meeting of the American College of Physicians, Michigan Chapter, Grand Traverse Village, Michigan, September 26-29, 1985.
12. Zinc absorption in uremia: Effect of 1,25 (OH) D, Regional Meeting of the American College of Physicians, Michigan Chapter, Grand Traverse Village, Michigan, September 26-29, 1985.
13. Hypercupremia in dialysis patients, Annual Meeting of the Midwest Section of the American Federation for Clinical Research, Chicago, Illinois, November 6-8, 1985.
14. Zinc balance studies in uremia, Central Society for Clinical Research, Chicago, Illinois, November 9-11, 1988.
15. The pattern of LH secretion and responsiveness to pulsatile GnRH in men with uremia. Central Society for Clinical Research. Chicago, Illinois, November 8-10, 1989.
16. Effect of vitamin D on zinc metabolism in uremia. Central Society for Clinical Research, Chicago, Illinois, November 8-10, 1989.
17. High incidence of Macrocytosis in dialysis patients National Kidney Foundation meeting, Illinois September 10-2006.

**Invited Presentations:**

1. Challenges in treatment of End Stage Renal Disease in AIDS and HIV patients. Meeting of the Michigan Chapter American Nephrology Nurses Association. Frankenmuth, Michigan, April 6, 1993